慶應医学会例会

下記のとおり例会を開催いたしますので、ふるってご来聴くださいますようお願い申し上げます。

日 時 2020 年 3 月 11 日 (水) 18 : 00
場 所 新教育研究棟2階講堂
演 題

Theta Burst Stimulation for Depression: Current Status and Future Directions

  Daniel Blumberger MD, MSc, FRCPC
Centre for Addiction and Mental Health Department of Psychiatry, University of Toronto
演 題

Innovative Solutions for Mental Health in Pregnancy and Postpartum

  Simone Vigod MD, MSc, FRCPC
Women's College Hospital Division of Equity, Gender and Population, Department of Psychiatry, Faculty of Medicine, University of Toronto
担 当

精神・神経科学 教室
責任者:三村 將 教授
担当者:野田 賀大 先生(内線 61857)

  以上
日 時 2020 年 2 月 18 日 (火) 18 : 00
場 所 孝養舎405教室
演 題

Traditional Chinese Medicine in Taiwan: Real-World Evidences from the Big Data Perspective

演 者 Professor Hung-Rong Yen, M.D., Ph.D.
Associate Dean, College of Chinese Medicine
China Medical University, Taiwan

Professor Hung-Rong Yen is a physician scientist with dual clinical training in Western medicine and Chinese medicine in China Medical University, Taiwan. Aside from laboratory and clinical studies, he has conducted and published more than 50 papers by big-data analysis in traditional Chinese medicine utilizations in Taiwan. He is a leading advocate of the integration of Chinese medicine into conventional care and builds bridges between doctors of all backgrounds.
担 当

漢方医学センター 教室(内線 61861)
責任者:三村 將 教授
担当者:渡辺 賢治 先生

  以上
日 時 2020 年 1 月 30 日 (木) 17 : 00
場 所 総合医科学研究棟1階ラウンジ
演 題

Regulatory T cells (Tregs) control of non-immunological functions

演 者 Diane Mathis, PhD, Professor
Division of Immunology, Dept. of Microbiology & Immunobiology
Harvard Medical School, Boston, MA 02115, USA.

ハーバード大学教授Diane Mathis博士は免疫学の世界では著名で先端分野を開拓してこられた碩学です。本講演ではDiane博士らが発見された組織内制御性T細胞(Treg)の組織恒常性維持機構について講演していただきます。

参考論文:
Tissue Tregs.
Panduro M, Benoist C, Mathis D. Annu Rev Immunol. 2016 May 20;34:609-33.

Regulatory T cells in nonlymphoid tissues.
Burzyn D, Benoist C, Mathis D. Nature Immunol. 2013 Oct;14(10):1007-13.

Distinct immunocyte-promoting and adipocyte-generating stromal components coordinate adipose tissue immune and metabolic tenors.
Spallanzani RG, et al. Sci Immunol. 2019 May 3;4(35). pii: eaaw3658.

TCR Transgenic Mice Reveal Stepwise, Multi-site Acquisition of the Distinctive Fat-Treg Phenotype.
Li C et al. Cell. 2018 Jul 12;174(2):285-299.e12.

担 当

微生物学・免疫学 教室
責任者:吉村 昭彦 教授
担当者:(内線 61220)

  以上
日 時 2019 年 12 月 13 日 (金) 17 : 00
場 所 総合医科学研究棟1階ラウンジ
演 題

Engineering Exhaustion Resistant Stem-cell like T cells to Enhance the Efficacy of Cell Based Therapies

演 者 Madhusudhan Sukumar, PhD, Staff Scientisit
National Cancer Institute (NCI), NIH, Bethesda, MD

Dr. Sukumarは代謝および腫瘍環境における抗腫瘍性T細胞のメモリー分化、疲弊に関し非常に優れた研究を多数発表しています。T細胞療法や抗腫瘍免疫に関心のある皆さんの参加をお願いします。

参考論文:
A New Axis of Tumor Immunosuppression. Cell. 2015 Sep 10;162(6):1206-8.
Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. Cell Metab. 2016 Jan 12;23(1):63-76.
Ionic immune suppression within the tumour microenvironment limits T cell effector function.
Nature. 2016 ;537(7621):539-543.
Metabolic reprograming of anti-tumor immunity. Curr Opin Immunol. 2017 Jun; 46:14-22
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab. 2017 Jul 5;26(1):94-109.
Identification of essential genes for cancer immunotherapy. Nature 2017 Aug 31;548(7669):537-542.
T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science. 2019 Mar 29;363(6434).
担 当

微生物学・免疫学 教室
責任者:吉村 昭彦 教授
担当者:(内線 61220)

  以上
日 時 2019 年 11 月 19 日 (火) 18 : 00
場 所 JKiC 会議室
演 題

Equilibrium and disruption of host-microbial symbiosis

  Keisuke Chris Nagao M.D., Ph.D.
Cutaneous Leukocyte Biology Section, Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health
担 当

皮膚科学教室 教室
責任者:天谷 雅行 教授
担当者:高橋 勇人 先生(内線 62411)

  以上
日 時 2019 年 11 月 11 日 (月) 19 : 30
場 所 新教育研究棟2階講堂
演 題

The importance of heart rate control for the treatment of heart failure

  Piotr Ponikowski MD PHD,FESC,FHFA
Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland
担 当

循環器内科 教室
責任者:福田 恵一 教授
担当者:(内線 61420)

  以上
日 時 2019 年 11 月 8 日 (火) 19 : 00
場 所 リサーチパーク1階ラウンジ
演 題

PE management updated ESC PE guideline

  Stavros V Konstantinides MD, PhD
University of Mainz,Germany
担 当

循環器内科 教室
責任者:福田 恵一 教授
担当者:(内線 61420)

  以上
日 時 2019 年 10 月 11 日 (金) 16 : 00
場 所 総合医科学研究棟1階ラウンジ
演 題

Precision Stimulation Medicine

  Hartwig R Siebner M.D., Ph.D.
Danish Research Centre for Magnetic Resonance
演 題 Transcutaneous spinal stimulation for gait rehabilitation
  Toshiyuki Fujiwara M.D., Ph.D.
Department of Rehabilitation Medicine, Juntendo University School of Medicine / Graduate School of Medicine
演 題 Perspectives of TMS-EEG
  Leo Tomasevic Ph.D.
Danish Research Centre for Magnetic Resonance
演 題 Motor cortex GABAergic dysfunction in Italian patients with Familial adult myoclonic epilepsy (FAME)
  Raffaele Dubbioso M.D., Ph.D.
Department of Neuroscience and Reproductive and Odontostomatological Sciences, University of Naples Federico II
演 題 Effects of multiple sclerosis on TMS outcome measures
  Mads A.J. Madsen Ph.D. student
Danish Research Centre for Magnetic Resonance
演 題 Focal transcranial alternating current stimulation to the sensorimotor hand area at individual alpha and beta rhythm - effects on corticospinal excitability
  Mitsuaki Takemi Ph.D.
Division of Physical and Health Education, Graduate School of Education, The University of Tokyo
担 当

リハビリテーション医学 教室
責任者:里宇明元 教授
担当者:田代祥一 先生(内線 62264)

  以上
日 時 2019 年 9 月 30 日 (月) 18 : 00
場 所 総合医科学研究棟1階ラウンジ
演 題

Dissecting resistance to PD-1 blockade, one cell at a time

  Drew Mark Pardoll M.D., Ph. D.
Department of Pathology, Johns Hopkins University School of Medicine
  PD-1 pathway blockade has been approved for 16 different cancer types and is being tested in an additional 15. Despite its dramatic activity, the majority of patients do not respond to anti-PD-1 antibodies. We have shown that neoadjuvant anti-PD-1 given to lung cancer patients prior to resection of their primary tumor results in a nearly 50% major pathologic response rate (<10% of tumor bed consisting of viable tumor cells). This clinical format allowed us to obtain large numbers of TIL after anti-PD-1 therapy so that we could perform single cell transcriptomics and TCR repertoire analysis. As part of this analysis we could determine which genes and genetic programs were associated with successful anti-tumor response vs non-response. We found that T cells from non-responding tumors exhibited a broad stress response signature, while T cells from MPR tumors did not. While T cells from both responding and non-responding tumors expressed high levels of PD-1, PD-1+ T cells from non-responding tumors had higher levels of the canonical exhaustion factor TOX and other exhaustion-associated genes, including CD39, Tim3 and other checkpoints. T cells from non-responders demonstrated Treg from non-responding tumors were more numerous and expressed specific Treg inhibitory molecules. Taken together, T cells ronr-responding tumor encounter a high stress microenvironment and express high levels of transcriptional and membrane inhibitory molecules, some of which are therapeutically targetable.
演 題

PD-1 blockade a common denominator for cancer therapy

  Suzanne Louise Topalian M.D.
Department of Surgery and Oncology, Johns Hopkins University School of Medicine
  The PD-1 pathway, including the immune cell receptor Programmed Cell Death 1 (PD-1) and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), mediates immunosuppression in the tumor microenvironment. Drugs that "release the brakes" on anti-tumor immunity by blocking PD-1 or PD-L1 have shown substantial and durable activity in multiple cancers, validating them as a "common denominator" for cancer therapy. Since September 2014, the US FDA has approved 6 different PD-1/PD-L1 antibodies to treat advanced cancers, including 15 tumor types and the broad genetically-defined MSI-high category. These drugs are now being applied in earlier stages of cancer, in the adjuvant and neoadjuvant settings. Tumor PD-L1 protein expression correlates with enhanced responsiveness of some cancers to anti-PD-1, while tumor mutational burden, reflecting neoantigen load, associates with likelihood of response in additional patients. The continued interrogation of potential biomarkers is expected to further refine the risk:benefit profile for PD-1/PD-L1 antagonists, increase our understanding of the mechanistic underpinnings of this pathway, and guide the development of more effective combination therapies.
担 当

先端研(細胞) 教室
責任者:河上 裕 特任教授
担当者:谷口智憲 先生(内線 62708)

  以上
日 時 2019 年 9 月 24 日 (火) 17 : 00
場 所 臨床研究棟1階ラウンジ
演 題

Angiogenic factors: clinical implications in the management of preeclampsia

  Sofia Cerdeira MD, PhD
Nuffield Department of Obstetrics and Gynaecology, University of Oxford
  Preeclampsia is a complex disease with significant maternal and fetal morbidity and mortality. Its syndromic nature makes diagnosis and management difficult. Angiogenic factors, in particular soluble fms-like tyrosine kinase 1 (sFlt-1), have emerged as important molecules in the pathogenesis of preeclampsia and are regarded as potential biomarkers and therapeutic targets. We were the first unit in UK to implement sFlt1/PlGF ratio in clinical practice and are helping other units to do so. I will present our latest data and discuss present and future clinical implications on the use of angiogenic factors in the management of preeclampsia.
担 当

産婦人科学(産科学) 教室
責任者:田中 守 教授
担当者:池ノ上 学 先生(内線 62381)

 
  以上

†先頭へ

関連病院会 クリニック情報 住所変更依頼 トップページへ戻る